[8-K] Evoke Pharma, Inc. Reports Material Event

Rhea-AI Filing Summary

Fusion Fuel Green PLC (Nasdaq: HTOO) reports that, on 5 Aug 2025, the Nasdaq Hearings Advisor confirmed the company has regained compliance with Nasdaq Listing Rules 5620(a) (annual meeting requirement) and 5550(a)(2) (minimum $1.00 bid price). The decision removes the immediate risk of delisting and restores the company’s full listing status on the Nasdaq Capital Market. A press release detailing the ruling was furnished as Exhibit 99.1.

No financial results, guidance, or transactional updates were included in this Form 6-K. Management cautions that forward-looking statements remain subject to the risk factors outlined in the May 9 2025 Form 20-F.

Positive

• Nasdaq compliance regained, eliminating immediate delisting threat and preserving trading liquidity and investor access.

Negative

• None.

Insights

Equity Analyst

TL;DR: Nasdaq compliance restored; lowers delisting risk, mildly positive for equity perception.

The confirmation that HTOO now satisfies Rules 5620(a) and 5550(a)(2) removes a critical overhang that could have led to forced delisting or a reverse split. While the filing lacks financial data, continued listing preserves liquidity, index eligibility, and investor confidence. The event is incrementally positive but not transformational; future valuation will still hinge on execution of hydrogen projects and upcoming earnings disclosures.

Corporate Governance Specialist

TL;DR: Governance compliance achieved; signals improved internal controls.

Meeting the shareholder-meeting rule (5620(a)) indicates that board and management have aligned governance practices with U.S. exchange standards. Coupled with restoring bid-price compliance, this decision demonstrates responsive remediation of prior deficiencies. The panel’s ruling should reduce governance-related risk premiums, though ongoing monitoring is advised given prior non-compliance history.

0001403708false00014037082025-08-062025-08-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 06, 2025

EVOKE PHARMA, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-36075	20-8447886
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
420 Stevens Avenue, Suite 230
Solana Beach, California				92075
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 858 345-1494

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		EVOK		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 6, 2025, Evoke Pharma, Inc. (the “Company”) announced the official issuance of a new U.S. patent related to its product GIMOTI®. The patent, U.S. Patent No. 12,377,064, covers the use of intranasal metoclopramide in patients with moderate to severe symptoms of gastroparesis, and has now been issued by the United States Patent and Trademark Office ("USPTO"). The patent term has been extended by the USPTO to November 2038, due to patent term adjustments. The Company plans to list this newly issued patent in the FDA’s Orange Book.

Safe Harbor Statement

The Company cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include statements regarding: the timing of updated listing in the Orange Book. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: the Company’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in the Company’s periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Evoke Pharma, Inc.
Date:	August 6, 2025	By:	/s/ Matthew J. D'Onofrio
			Name: Maatthew J. D'Onofrio Title: Chief Executive Officer and Director

FAQ

Why did Fusion Fuel Green PLC file this Form 6-K?

To disclose Nasdaq’s decision confirming the company has regained compliance with Listing Rules 5620(a) and 5550(a)(2).

Which Nasdaq rules are now satisfied by HTOO?

Rule 5620(a) (annual shareholder meeting) and Rule 5550(a)(2) (minimum $1.00 bid price).

Does the filing include financial results for Fusion Fuel Green?

No. The Form 6-K only reports the compliance decision; no revenue or earnings data were provided.

When was the compliance decision received?

The decision was received on August 5, 2025 and reported on August 6, 2025.

What impact does Nasdaq compliance have on HTOO shareholders?

It removes delisting risk, maintains market liquidity, and avoids potential corporate actions like reverse splits.